OCC Secures Access to 221 U.S. Military Medical Centres
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Orthocell Ltd has secured approval to sell its Remplir nerve repair device to the U.S. Department of Defence and Veterans Affairs hospital networks, which includes numerous military hospitals and medical centres. This approval marks a significant milestone in expanding Orthocell's access to the U.S. market and will enable the company to engage directly with military surgeons. The Remplir device has already shown its effectiveness in treating conflict-related injuries, particularly in Ukraine, demonstrating its suitability for military healthcare needs. Orthocell plans to leverage its existing distributor network to target these military and VA surgeons, enhancing its market penetration in the U.S.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Orthocell
- Remplir Used in 23 Surgeries in Ukrainian soldiers
- Orthocell Appoints UK Distributor for Remplir
- Appendix 4D & Half-Year Financial Report
- Orthocell Receives $3.0m R&D Tax Refund
- US Market and Operational Update
Later from Orthocell
- Orthocell Secures Approval to sell Remplir™ to the U.S. Department of Defence Hospital Network
- First Surgical Use of Remplir in US Department of Defense
- Q3 FY26 Investor Presentation
- Compelling 90% Success Rate for Remplir in Real World Study
- First Sales of Remplir Achieved in US$75m Canadian Market
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell